Tagamet 100
This article was originally published in The Tan Sheet
Executive Summary
SmithKline Beecham receives license in the U.K. to market its 100 mg nonprescription formulation of the H[2] antagonist cimetidine for the relief of heartburn and dyspepsia, the company announced March 9. The OTC product is expected to be available "in the near future," SmithKline Beecham said. Cimetidine was one of 11 Rx-to-OTC switches approved by the U.K. Medicines Control Agency in a Jan. 21 order ("The Tan Sheet" Feb. 21, p. 6). J&J- Merck's H[2] antagonist famotidine, launched as Pepcid AC by the joint venture's new U.K. subsidiary, Centra Health Care, was also switched on Jan. 21; however, only cimetidine is indicated for the prevention of nocturnal heartburn as well as daytime treatment. Labeling directs consumers to take either two 100 mg tablets at the onset of symptoms, or one 100 mg tablet prophylactically at bedtime
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning